Robert B Ford sold $46M of ABT
CHAIRMAN AND CEO at ABBOTT LABORATORIES. 398,832 shares at an average of $115.85, traded Aug 25, 2026, filed Aug 27, 2026.
Score components
- +25RoleCEO
- +25Trade size$46.2M at market
- +20Share of holdings soldSold 57% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001612571-26-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | MOption exercise Common shares without par value | +151,869 | $44.40 | $6.7M | 458,330 | Aug 27, 2026 |
| Aug 25, 2026 | MOption exercise Common shares without par value | +246,963 | $59.94 | $15M | 705,293 | Aug 27, 2026 |
| Aug 25, 2026 | SOpen-market sale Common shares without par value | -218,535 | $115.57 | $25M | 486,758 | Aug 27, 2026 |
| Aug 25, 2026 | SOpen-market sale Common shares without par value | -180,297 | $116.19 | $21M | 306,461 | Aug 27, 2026 |
| Aug 25, 2026 | MOption exercise Option (right to buy)derivative | -151,869 | $0.00 | $0 | 0 | Aug 27, 2026 |
| Aug 25, 2026 | MOption exercise Option (right to buy)derivative | -246,963 | $0.00 | $0 | 0 | Aug 27, 2026 |
Related signals
Other insiders at ABBOTT LABORATORIES and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $2,958 27 shares | -0% | |
| 43Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $643k 5,850 shares | -8% | |
| 62Notable | ABBOTT LABORATORIES | John G Stratton director | $174k 2,000 shares | +9% | |
| 72Notable | ABBOTT LABORATORIES | Daniel J Starks director | $927k 10,000 shares | +0% | |
| 75Notable | ABBOTT LABORATORIES | Philip P Boudreau EVP AND CFO | $201k 2,200 shares | - | |
| 40Moderate | ABBOTT LABORATORIES | Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT | $102k 885 shares | -1% | |
| 48Moderate | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $68k 585 shares | -2% | |
| 48Moderate | ABBOTT LABORATORIES | Mary K Moreland EXECUTIVE VICE PRESIDENT | $71k 613 shares | -1% | |
| 51Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $132k 1,144 shares | -1% | |
| 39Weak | ABBOTT LABORATORIES | Eric Shroff Senior Vice President | $82k 709 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.